- Home
- AXSM
as 06-20-2025 4:00pm EST
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.1B | IPO Year: | 2015 |
| Target Price: | $170.50 | AVG Volume (30 days): | 627.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $72.02 - $139.13 | Next Earning Date: | 08-04-2025 |
| Revenue: | $432,157,000 | Revenue Growth: | 72.16% |
| Revenue Growth (this year): | 62.84% | Revenue Growth (next year): | 60.02% |
Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Murdock Hunter R. | AXSM | General Counsel | Jun 16 '25 | Sell | $101.19 | 22,500 | $2,276,850.00 | 0 | |
| Jacobson Mark L. | AXSM | Chief Operating Officer | May 27 '25 | Sell | $104.06 | 40,673 | $4,232,636.18 | 5,783 | |
| Coleman Mark | AXSM | Director | May 27 '25 | Sell | $104.45 | 7,500 | $783,375.00 | 46,637 | |
| Coleman Mark | AXSM | Director | May 20 '25 | Sell | $107.49 | 3,000 | $322,473.00 | 46,637 |
Latest Axsome Therapeutics Inc. News
AXSM Breaking Stock News: Dive into AXSM Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
Simply Wall St.
3 days ago
Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven?
GlobeNewswire
3 days ago
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
GlobeNewswire
5 days ago
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
Insider Monkey
9 days ago
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
GlobeNewswire
10 days ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
GlobeNewswire
11 days ago
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
GlobeNewswire
12 days ago
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
Compare AXSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXSM Axsome Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.